Watson Receives FDA Approval For Oxycodone And Acetaminophen Tablets USP, 7.5 Mg/500 Mg And 10 Mg/650 Mg

CONTACTS:
Watson Pharmaceuticals, Inc.
Sara Swee
Director, Corporate Communications
(909) 270-1400

Morgen-Walke Associates, Inc.
Jim Byers (Investors)
Christopher Katis (Press)
(415) 296-7383

FOR IMMEDIATE RELEASE

WATSON RECEIVES FDA APPROVAL FOR
OXYCODONE and ACETAMINOPHEN TABLETS USP,
7.5 MG/500 MG and 10 MG/650 MG

CORONA, CA - January 3, 2001 - Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that the Food and Drug Administration (FDA) has approved Watson's abbreviated new drug application (ANDA) for Oxycodone and Acetaminophen Tablets USP, 7.5 mg/500 mg and 10 mg/650 mg.

Oxycodone and Acetaminophen Tablets are the generic equivalent to Endo Pharmaceuticals' Percocet® Tablets, which are indicated for the treatment of moderate to moderately severe pain. This product will be manufactured by Watson's Miami, Florida facility.

This press release may contain forward-looking statements relating to Watson's future business performance, which involve risks and uncertainties that cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, among others, those detailed in Watson's Securities and Exchange Commission filings.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products.

This and past press releases of Watson Pharmaceuticals, Inc. are available at Watson's web site at www.watsonpharm.com. In addition, press releases are available through PR Newswire's Company On-Call fax service at (800) 758-5804, extension 112856, and at www.prnewswire.com.

# # #


distributed by